Tier 2 — strong

Effect of quercetin on paraoxonase 2 levels in RAW264.7 macrophages and in human monocytes--role of quercetin metabolism

Christine Boesch-Saadatmandi, Renata Toedter Pospissil, Anne-Christin Graeser, Raffaella Canali, Inka Boomgaarden, Frank Doering, Siegfried Wolffram, Sarah Egert, Manfred James Mueller, Gerald Rimbach
International journal of molecular sciences 2009 10(9):4168

Bibliography

PubMed
PMID 19865538
PubMed Central
PMC2769159
DOI
10.3390/ijms10094168
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignHuman supplementation study with murine cell experiments
ModelMixed human intervention and laboratory research
SampleAdults with overweight and cardiovascular-risk traits; clinical sample size not stated in the abstract
InterventionQuercetin 150 mg/day; separate macrophage experiments at micromolar concentrations
Duration42 days in humans
EndpointsProtein activity, binding or signaling

What the study showed, in plain terms

Published in 2009, this source examined evidence reviews and human mechanisms. Design: Human supplementation study with murine cell experiments. Sample/model: Adults with overweight and cardiovascular-risk traits; clinical sample size not stated in the abstract. The exposure or intervention was Quercetin 150 mg/day; separate macrophage experiments at micromolar concentrations. Follow-up or treatment period: 42 days in humans.

Quercetin increased PON2 expression in cultured macrophages but not in circulating human monocytes after supplementation.

The favorable cell result did not translate to the measured human endpoint. Likely related to the same cardiovascular-risk intervention reported elsewhere.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin Benefits: What Human Studies Actually Show. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Quercetin increased PON2 expression in cultured macrophages but not in circulating human monocytes after supplementation.
  • The recorded outcome domains were Protein activity, binding or signaling.
  • The result applies to the tested exposure: Quercetin 150 mg/day; separate macrophage experiments at micromolar concentrations; 42 days in humans.

What this study can and cannot tell us

  • The favorable cell result did not translate to the measured human endpoint. Likely related to the same cardiovascular-risk intervention reported elsewhere.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Companion or correction records are linked below. They should not be counted automatically as independent replications; see the individual source notes for the relationship.
  • Source basis: Source check: accessible full text and indexed metadata. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: a double-blinded, placebo-controlled cross-over study
Sarah Egert et al. · The British journal of nutrition · 2009
Tier 2
Serum lipid and blood pressure responses to quercetin vary in overweight patients by apolipoprotein E genotype
Sarah Egert et al. · The Journal of nutrition · 2010
Tier 2
Quercetin supplementation and its effect on human monocyte gene expression profiles in vivo
Inka Boomgaarden et al. · The British journal of nutrition · 2010

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology